X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis

Company Overview

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by abnormalities in the immune system. The company’s research is centered on the CXCR4 pathway, which helps regulate the movement and distribution of immune cells in the body.

X4’s lead product, XOLREMDI (mavorixafor), is an orally administered CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for patients aged 12 and older with WHIM syndrome. WHIM syndrome is a rare, inherited immunodeficiency characterized by chronic neutropenia, low levels of other white blood cells, and increased susceptibility to infections. XOLREMDI is designed to increase circulating neutrophils and lymphocytes and is intended for long-term treatment of the condition.

The company’s activities are primarily focused on the United States, where it is commercializing XOLREMDI while continuing to evaluate mavorixafor in additional rare-disease and immune-cell disorders. X4 Pharmaceuticals was founded as a biotechnology company developing CXCR4-targeted medicines and became a publicly traded company on the Nasdaq exchange in 2019.

Key Stats

• Today's Range: $2.75 to $2.86
• 50-Day Range: $2.83 to $4.64
• 52-Week Range: $2.74 to $4.83
• Volume: 911,397 shs
• Average Volume: 1.26 million shs
• Market Capitalization: $280.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.25
• Consensus Rating: Moderate Buy

X4 Pharmaceuticals Stock Analysis - MarketRank™

X4 Pharmaceuticals scored higher than 31% of companies evaluated by MarketBeat, and ranked 731st out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

X4 Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

X4 Pharmaceuticals has a consensus price target of $11.25, representing about 297.5% upside from its current price of $2.83.

Amount of Analyst Coverage

X4 Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for X4 Pharmaceuticals are expected to decrease in the coming year, from ($0.67) to ($0.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of X4 Pharmaceuticals is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of X4 Pharmaceuticals is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

X4 Pharmaceuticals has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.40% of the float of X4 Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

X4 Pharmaceuticals has a short interest ratio ("days to cover") of 7.07.

Change versus previous month

Short interest in X4 Pharmaceuticals has recently increased by 14.55%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

X4 Pharmaceuticals does not currently pay a dividend.

Dividend Growth

X4 Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for X4 Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for XFOR on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, X4 Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $319,733.00 in company stock.

Percentage Held by Insiders

1.13% of the stock of X4 Pharmaceuticals is held by insiders.

Percentage Held by Institutions

72.03% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:XFOR
• CIK: 1501697
• Web: www.x4pharma.com
• Phone: (857) 529-8300
• Fax: N/A
• Employees: 45
• Year Founded: 2010

Price Target and Rating

• Average Price Target for X4 Pharmaceuticals: $11.25
• High Price Target: $12.00
• Low Price Target: $10.00
• Potential Upside/Downside: +297.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$79.20 million
• Net Margins: -568.80%
• Pretax Margin: -568.98%
• Return on Equity: -63.05%
• Return on Assets: -36.89%

Debt

• Debt-to-Equity Ratio: 0.49
• Current Ratio: 11.30
• Quick Ratio: 11.02

Sales & Book Value

• Annual Sales: $15.85 million
• Price / Sales: 17.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.13 per share
• Price / Book: 1.33

Miscellaneous

• Outstanding Shares: 99,147,000
• Free Float: 98,027,000
• Market Cap: $280.59 million
• Optionable: No Data
• Beta: 0.46